Physician profile
Christopher A Scheiner
NPI 1487864773
$406,476.50
in general payments reported to CMS, 2019-2025
55 companies · $198K in 2025
The $198K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $223 · 2021: $1,324 · 2022: $24K · 2023: $35K · 2024: $147K · 2025: $198K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $233K · Travel and Lodging: $90K · Consulting Fee: $42K · Food and Beverage: $15K · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $233,341.00 |
| Travel and Lodging | $90,120.32 |
| Consulting Fee | $41,605.71 |
| Food and Beverage | $15,058.84 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $198,524.16 | 2019-2025 | Ultomiris, Soliris |
| Csl Behring | $154,715.95 | 2020-2025 | Hizentra, Privigen |
| Amgen INC. | $18,924.52 | 2025 | Uplizna |
| Argenx US, INC. | $15,376.49 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Janssen Biotech, INC. | $11,182.76 | 2025 | Tremfya |
| Ucb, INC. | $4,147.93 | 2022-2025 | Rystiggo, Zilbrysq, Briviact |
| Janssen Scientific Affairs, LLC | $322.41 | 2024-2025 | |
| Biogen, INC. | $282.73 | 2022-2025 | Spinraza, Skyclarys, Spinraza |
| Genzyme Corporation | $179.00 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $161.02 | 2024-2025 | Wainua |
| Akcea Therapeutics, INC. | $156.15 | 2019 | |
| Alnylam Pharmaceuticals INC. | $152.24 | 2020-2025 | Amvuttra |
| Biohaven Pharmaceuticals, INC. | $145.28 | 2020-2021 | |
| Allergan, INC. | $136.71 | 2020-2022 | |
| Genentech USA, INC. | $115.03 | 2022-2024 | Ocrevus, Evrysdi |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Scheiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.